@article {7741,
	title = {Prognostication of the high-risk WM patient},
	journal = {Clinical Lymphoma, Myeloma and Leukemia},
	volume = {11},
	year = {2011},
	note = {Export Date: 21 February 2017},
	month = {2011},
	pages = {127 - 129},
	abstract = {Waldenstr{\"o}m{\textquoteright}s macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these "poor-risk" patients, we identified patients who died within 2 years from the initiation of front-line treatment. These patients were older and had more often features of aggressive disease, such as elevated LDH and low serum albumin than the standard-risk population. Furthermore, only a minority of poor-risk patient had a response to initial therapy. However, conventional clinical factors or even the lack on response could not adequately identify poor-risk patients, indicating the need for novel molecular or other markers that would be able to effectively recognize patients at greatest need for aggressive therapies. {\textcopyright} 2011 Elsevier Inc. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953707927\&doi=10.3816\%2fCLML.2011.n.028\&partnerID=40\&md5=9fd65f9357a5d3460f98dedb685bb722},
	author = {Kastritis, E. and Gavriatopoulou, M. and Kyrtsonis, M.-C. and Michael, M. and Hadjiharissi, E. and Symeonidis, A. and Michalis, E. and Repoussis, P. and Tsatalas, K. and Sioni, A. and Kartasis, Z. and Stefanoudaki, E. and Voulgarelis, M. and Delimpasi, S. and Gika, D. and Vervesou, E. and Konstantopoulos, K. and Kokkini, G. and Zomas, A. and Roussou, P. and Anagnostopoulos, N. and Economopoulos, T. and Terpos, E. and Zervas, K. and Dimopoulos, M.A.}
}
